Basics Aclaris Therapeutics, Inc. Aclaris Therapeutics Inc is a clinical-stage specialty pharmaceutical company which focuses on identifying, developing and commercializing differentiated drugs to address significant unmet needs in dermatology. IPO Date: October 7, 2015 Sector: Healthcare Industry: Biotech Market Cap: $217.75M Activated in VL: True Average Daily Range Avg Daily Range: $0.34 | 3.17% Avg Daily Range (30 D): $0.06 | 3.28% Avg Daily Range (90 D): $0.05 | 2.81% Institutional Daily Volume Avg Daily Volume: .67M Avg Daily Volume (30 D): 1.09M Avg Daily Volume (90 D): .92M Trade Size Avg Trade Size (Sh.): 153 Avg Trade Size (Sh.) (30 D): 214 Avg Trade Size (Sh.) (90 D): 191 Institutional Trades Total Inst.Trades: 1,168 Avg Inst. Trade: $1.57M Avg Inst. Trade (30 D): $.97M Avg Inst. Trade (90 D): $3.07M Avg Inst. Trade Volume: .14M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $1.5M Avg Closing Trade (30 D): $1.44M Avg Closing Trade (90 D): $6.14M Avg Closing Volume: 143.25K     News Sep 9, 2025 @ 11:00 AM Aclaris Therapeutics Announces Late-Breaking Abstr... Source: Aclaris Therapeutics Aug 27, 2025 @ 12:00 PM Aclaris Therapeutics to Participate in Two Septemb... Source: Will Roberts May 9, 2025 @ 11:00 AM Aclaris Therapeutics to Participate in the HC Wain... Source: N/A Apr 29, 2025 @ 11:00 AM Aclaris Therapeutics Appoints Jesse Hall, M.D. as ... Source: N/A Mar 3, 2025 @ 6:00 PM JAK Inhibitors Clinical Trial Pipeline Appears Rob... Source: Delveinsight Financials   TTM Q2 2025 Q1 2025 Basic EPS $-1.57 $-.13 $-.12 Diluted EPS $-1.57 $-.13 $-.12 Revenue $ 16.79M $ 1.78M $ 1.46M Gross Profit $ 14.41M $ 1.26M $ .95M Net Income / Loss $ -134.65M $ -15.43M $ -15.09M Operating Income / Loss $ -146.64M $ -18.41M $ -18.08M Cost of Revenue $ 2.38M $ .52M $ .51M Net Cash Flow $ 2.57M $ -4.96M $ 5.79M PE Ratio